Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment

Summary

This narrative review synthesises recent genetic and clinical evidence demonstrating that apoB concentration—which quantifies the total number of circulating atherogenic lipoproteins—may be a superior proxy to LDL-cholesterol for assessing atherosclerotic cardiovascular disease risk, particularly in patients with diabetes, metabolic syndrome, insulin resistance, hypertension, elevated triglycerides, or very low LDL-cholesterol levels. The authors argue that since each LDL, IDL, and VLDL particle contains exactly one apoB molecule, apoB measurement is independent of particle density heterogeneity and lipid content variation, offering improved risk stratification. The review recommends routine simultaneous measurement of both LDL-cholesterol and apoB to properly estimate global cardiovascular risk and monitor treatment efficacy.

Regional applicability

The study does not appear to report a specific geographic location, instead presenting a clinical evidence review applicable to cardiovascular prevention practices internationally. The findings would be directly relevant to United Kingdom clinical practice and preventive cardiology, where this evidence could inform refinement of lipid risk stratification protocols in the NHS, particularly for patients with cardiometabolic comorbidities.

Key measures

Apolipoprotein B levels; LDL-cholesterol levels; atherogenic particle number; cardiovascular disease risk stratification in specific patient subgroups

Outcomes reported

The study reviewed evidence comparing apolipoprotein B (apoB) measurement with low-density lipoprotein cholesterol (LDL-C) for assessing atherosclerotic cardiovascular disease risk. It identified specific patient subgroups—including those with diabetes, metabolic syndrome, elevated triglycerides, and very low LDL-cholesterol—where apoB may be a superior risk marker.

Topic tags